Market Overview

Cultivating the Cognac of Cannabis Strains


Cultivating the Cognac of Cannabis Strains

PR Newswire

PALM BEACH, Florida, March 27, 2018 /PRNewswire/ -- News Commentary 

It is expected that 2018 will be the milestone year that Canada legalizes recreational cannabis, signaling an end to a long period of cannabis prohibition in the country. In a historical parallel, the 20th century witnessed a 14-year period of alcohol prohibition in the United States, and today, alcohol is a multi-billion dollar mainstream market. Big brand names that now dominate the alcohol industry do so because they created brand loyalty over time through research and development that produced the most popular elixirs. In the cannabis market, Aurora Cannabis Inc. (TSX:ACB) (OTC:ACBFF), Supreme Cannabis Company Inc (TSXV:FIRE) (OTC:SPRWF), Canopy Growth Corp. (TSX:WEED) (OTC:TWMJF), Maple Leaf Green World Inc. (TSXV:MGW) (OTCQB:MGWFF) and RavenQuest Biomed Inc. (CSE:RQB) (OTC:RVVQF) (Frankfurt:1IT) are companies that are using research and development strategies in a race to cultivate the 'Cognacs' of cannabis.

The Canadian cannabis industry has already evolved into what Deloitte estimates is an $8 billion market - and it is expected to keep growing. As the recreational use market evolves, new scientific knowledge is being developed. Great scientific minds are working to identify and sequence what will make a strain better - and ultimately more popular.

Like developing the bouquet of a fine scotch, cannabis needs to go through this research and development transformation as well. RavenQuest BioMed Inc., a relatively little-known Canadian cannabis company, is building on a knowledge base to increase scientific understanding of cannabis genetics, with an endgame in mind to gaining consumer trust through delivering a consistent product, a key step towards developing a brand.

Mapping the 'Pot Genome' 

Scientific knowledge is somewhat limited since cannabis has been listed as a controlled substance for many decades. In this new age of cannabis consumption, cultivar (the scientific term for strain) recognition is going to be important. Consumers will want to know exactly what they are consuming, and they will likely develop loyalty towards the brands they like.

Loyal Cognac lovers don't order VSOP brandy - they order Cognac by name. Legendary liquor baron Joseph Seagram used research and development to master alcohol distillation, and out of that alchemy, the famed Seagram's Seven Crown Whiskey emerged. In the parallel world of cannabis, brand recognition will emerge as specific cultivars gain popularity. Scientists know this, and they are already studying the genetic structures of cannabis plants.

DNA became a household word when scientists famously mapped the pig genome years ago, and scientists are now mapping the 'pot genome'. RavenQuest BioMed Inc. is one contender that has taken a highly scientific approach towards developing strains that are unique enough for consumers to identify with and ideally develop a brand affinity for.

The company has hired experts in genetics, botany, and biochemistry, and has partnered with scientists at McGill University in Montreal who are doing cannabis research and development at the academic level. The research team is focused on key issues facing the cannabis industry surrounding cultivar recognition, identification, and stabilization. Dr. Donald Smith, who famously patented technologies for improvement of crop yields, has isolated, identified and mapped out plant genetics. Research and development in a laboratory environment moves the cannabis industry away from 'grassroots' and towards pharmaceutical grade production.

Building the Ultimate Bud Brand 

All of this research is ultimately aimed at improving cannabis strains to create 'bud brands' that will appeal to sophisticated recreational cannabis users. "Original Gangsta (OG) Kush" is one of the most popular mainstream cultivars, and has been cited for making up "the genetic backbone" of west coast cannabis varieties. Avid cannabis consumers order OG Kush by name, and the cultivar has been completely DNA sequenced. RavenQuest BioMed Inc. purchased 1,200 DNA snippets of many cultivars, including OG Kush, to be grown - as well as to obtain plant breeder's rights for newly developed OG Kush cultivars.

The research team is creating numbered codes based on cultivar recognition, where digits represent either sativa, indica, or a hybrid. The company separated out the cannabinoids (CBD), which are known to provide pain relief for the medical market, and the tetrahydrocannabinol (THC), which is the psychoactive ingredient in cannabis used for the recreational market. Then they measured the performance within each cultivar.

These processes are important because the future of the cannabis industry will be focused on cultivating healthy plants of the utmost potency and purity. In the medical market, this can protect patients from unwanted side effects and ensure pain relief, and in the recreational market, it can ensure the quality and consistency of the experience. Companies like RavenQuest BioMed Inc. are creating cultivars that could potentially dominate the cannabis market, such as high-end brands like Cognac and Grey Goose dominate in the liquor market.

Scientists are also working towards bringing drug identification numbers (DIN) to the cannabis industry, so consumers will be able to reference the DIN on a product prior to purchase. This happens in the pharmaceutical and nutraceutical worlds - and it is coming to the cannabis world. There will be numbering, sequencing, and efficacy testing that will certify that the product is consistent. This will create the foundation for naming branded cultivars in the cannabis industry, similar to how the alcohol industry names a VSOP like Cognac.

Orbital Gardens: Producing Pure and Potent Plants 

Consistency isn't the only ingredient needed to create a world-famous cannabis brand. Once the brand becomes popular, a challenge will be developing that brand at scale. This is an area where RavenQuest Biomed Inc. has an interesting edge. The company created what they call Orbital Gardens, which are architecturally unique to the industry. The Orbital Gardens optimize space with strategic placements. Most cannabis producers are focused on adding square footage, rather than using existing square footage more efficiently.

The architecture of the Orbital Gardens has mastered the efficient use of square footage and lighting by taking advantage of vertical space. Each Garden positions the plants so they are 'orbited' around a massive, bright light source - like planets orbiting around the sun. Imagine hundreds of plants rotating 360 degrees around the light and harnessing the power of photosynthesis. Orbital Gardens also recapture and recondition water and nutrients, feeding powerful, PH-balanced, nutrient-infused water back to the plants' root structures.

Orbital Gardens yield 300 grams per square foot. That is double the industry average of 130 grams per square foot - and it sets the stage for production potential that can satisfy even the highest levels of demand that will inevitably arise from creating a mainstream commercial cannabis brand.


Canopy Growth Corp, (TSX:WEED) (OTC:TWMJF) formerly known as Tweed Marijuana Inc., was founded by Bruce Linton in 2014 and is based in Smiths Falls, Ontario. Canopy is the first federally regulated, publicly traded cannabis producer in North America and is Canada's largest producer. It operates numerous production facilities across Canada and around the world with over 700,000 square feet of products licensed under Canada's medical cannabis framework.

Aurora Cannabis (TSX:ACB) (OTCQX:ACBFF) is a licensed producer of medical cannabis with a 55,200-square-foot facility in Mountain View County, Alberta. Recently, Aurora entered an agreement to buy CanniMed Therapeutics Inc., another Canadian-based medical cannabis company.

Maple Leaf Green World Inc. (TSXV:MGW) (OTCQB:MGWFF) Maple Leaf Green World is a British Columbia based company pursuing opportunities within the medical cannabis industry in the United States. If and when the Access to Cannabis for Medical Purposes Regulations ACMPR license is obtained, Maple Leaf GreenWorld will become a Canadian licensed producer. It is currently at a stage-5 review of the ACMPR application and in the process of building a new growing facility in Telkwa, B.C.

Supreme Cannabis Company Inc. (TSXV:FIRE) (OTC:SPRWF) established the 7ACRES property as the first licensed producer focused on growing high-quality cannabis in high quantities. Today 7ACRES is among Canada's leading cultivators of commercial cannabis. Based in Toronto, Supreme Cannabis Company recently completed a $3 million strategic equity investment in BlissCo Cannabis Corp., a Vancouver-based company that has applied to become a licensed producer under the ACMPR.

The Cannabis Industry of the Future 

The already $8 billion cannabis industry is becoming increasingly more attractive to investors as recreational legalization looms on the horizon. The race is on for cannabis companies to become household names, and companies like RavenQuest Biomed Inc. (CSE:RQB) (OTC:RVVQF) (Frankfurt:1IT) are already figuring out how to differentiate themselves by creating and defining their own unique signature brands.

For an in-depth look at RavenQuest Biomed Inc. (CSE:RQB) (OTC:RVVQF) (Frankfurt:1IT) visit for a full report.

DISCLAIMER: (MSC) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.


 The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty four hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Ravenquest Biomed Inc.



This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

Media Contact:

FN Media Group, LLC



View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at